Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.

doi:10.1007/s10120-024-01468-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 May 2024

Puliga Elisabetta, De Bellis Chiara, Vietti Michelina Sandra, Capeloa Tania, Migliore Cristina, Orrù Claudia, Baiocchi Gian Luca, De Manzoni Giovanni, Pietrantonio Filippo, Reddavid Rossella, Fumagalli Romario Uberto, Ambrogio Chiara, Corso Simona, Giordano Silvia

Abstract excerpt

BACKGROUND: Gastric cancer (GC) is the third leading cause of cancer-related death worldwide, with a poor prognosis for patients with advanced disease. Since the oncogenic role of KRAS mutants has been poorly investigated in GC, this study aims to biochemically and biologically characterize different KRAS-mutated models and unravel differences among KRAS mutants in response to therapy. METHODS: Taking advantage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HER2/EGFR in Cancer Research

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Protein Kinase Inhibitors

Share to Protein Kinase Regulation and GTPase Signaling

Share to Proto-Oncogene Proteins p21(ras)

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38261067
DOI: 10.1007/s10120-024-01468-8
PMCID: PMC11016506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.PMID 38261067Read ↗

Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles.Semantic proximity Read ↗

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Semantic proximity Read ↗

Oncogene addiction to GNAS in GNASR201 mutant tumors.Semantic proximity Read ↗

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell linesSemantic proximity Read ↗

Association of G12D mutation in the KRAS gene with HPV and EBV in gastrointestinal cancer tissues.Semantic proximity Read ↗

KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.